Alivus Life Sciences is an Indian API manufacturer and CDMO player, selling active pharmaceutical ingredients to generic customers across regulated and emerging markets while also offering contract development and manufacturing to specialty innovators. Its non-GPL business now contributes 71% of revenue, while the GPL relationship, a large legacy customer with more than 50 commercial products, still accounts for roughly 29% and is expected to stay flattish after a 52.6% decline in Q1 FY27 due to inventory rationalization. The company achieved an EBITDA margin of 36.6% in Q1 FY27 and 33.6% for FY26, with gross margins above 60% in the same quarter, reflecting a mix skewed toward non-commoditized, higher-entry-barrier molecules. With 176 molecules and 617 DMF/CEP filings, Alivus operates in a fragmented generic API landscape, but its margin level, which is among the highest in the Indian API industry, suggests pricing power and process efficiency rather than a pure scale game.
The economics persist because of regulatory approvals, customer qualification cycles, and process technology. Alivus has a clean compliance record, with the FDA issuing VAI at Ankleshwar and NAI at Dahej, which means fewer audits and easier market access. Its solvent recovery capability is a cited competitive advantage, and a new membrane-based recovery technology is expected to improve solvent recovery by 5 to 10%, directly supporting margins even as raw material prices rise. The CDMO business, which contributed 7% of FY26 revenue, operates on longer-term contracts with 1 to 1.5-year project lead times, and the company's focus on lifecycle management and specialty projects avoids the large $50-100M opportunities that attract more competition. Backward integration, flow chemistry, and a high-potent API pipeline of 29 products (13 validated) create barriers that are difficult to replicate quickly, as these require years of regulatory validation.
The inflection comes from capacity expansion and new product commercialization. Solapur Phase 1, originally slated for Q4 FY26, is now expected to be operational in early Q3 FY27 (around October-December 2026), and a major regulatory agency inspection is planned within a year of start-up, which would allow it to serve regulated markets by late FY28. The Solapur facility includes a 370 KL backward integration block and a 120 KL API block, and will initially run at 40-50% utilization. Meanwhile, brownfield expansions at Ankleshwar and Dahej, adding 110 KL and 160 KL respectively, are on track for operational readiness in Q2 FY27. Total reactor capacity is set to rise from 1,198 KL in FY24 to 2,690 KL by FY28. The non-GPL segment grew 26.5% YoY in Q1 FY27 and is guided to continue double-digit growth, while CDMO revenue, which recovered with 100% QoQ growth in Q3 FY26, is expected to gain momentum in H2 FY27 with two new contracts. High-potent API launches, targeting a $82 billion addressable market, are scheduled to begin around the end of calendar 2027, providing a 4-5 year growth runway. By 18-24 months from now, the business should have Solapur operational and inspected, brownfield capacities running at 80-90% utilization, and high-potent products starting to generate commercial sales, driving revenue growth into the double digits from FY28-FY29.
Management has a consistent record of delivering on its guidance. In the Aug-25 call, they guided high single-digit revenue growth for FY26 and EBITDA margins of 28-30%; they printed 7.2% growth for 9M FY26 and 33.3% EBITDA margin, beating the top end. Capex guidance was trimmed from ₹600 cr to ₹450 cr for FY26, with ₹150 cr deferred to FY27, which was presented as a calibration rather than a miss. The Solapur start-up slipped from Q4 FY26 to early Q3 FY27, but was flagged proactively and does not change near-term numbers. For FY27, management guides 10-12% revenue growth and 30-32% EBITDA margins, with potential to reach 34% if raw material costs do not spike further. They expect to conclude two new CDMO deals in early H2 FY27, and project high-potent API revenue to become meaningful from FY28. The balance sheet remains debt-free with cash and investments of ₹880 crore as of June 30, 2026, and the ₹540 crore FY27 capex is fully funded through internal accruals.
The earnings path over the next 18-24 months is underpinned by non-GPL growth (26.5% in Q1 FY27), CDMO scaling from five projects to seven or more, and the initial contribution from high-potent APIs. Assuming FY27 revenue growth of 10-12% and EBITDA margin of 30-32%, EBITDA should grow in the low to mid-teens, with further acceleration possible as Solapur ramps and regulated-market sales begin in late FY28. The key falsifier is execution on the Solapur inspection timeline and CDMO deal closures; if the inspection slips beyond a year or the two CDMO deals do not materialize, the growth trajectory could be pushed out. Additionally, raw material inflation (solvents and KSMs) could compress margins above the guided range, though partial pass-through is occurring. The most important watchpoint is the ramp-up and regulatory acceptance of Solapur, since it unlocks both backward integration benefits and regulated-market capacity.
companyname: Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) ticker: ALIVUS sector: Pharmaceuticals - Active Pharmaceutical Ingredients (APIs) and CDMO services Alivus Life Sciences is an independently managed developer and manufacturer of Active Pharmaceutical Ingredients (APIs), focused on high-value, non-commoditised molecules in chronic therapeutic areas. The company was carved out from Glenmark Pharmaceuticals in 2019, listed in 2021, and Nirma Limited acquired major...
Read the full report →capex, margin expansion
Capacity expansion to increase from 1,198 KL to 2,690 KL by FY28 driven by Solapur and backward integration projects
Guidance maintainedconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Alivus Life Sciences Ltd. and 4,900+ companies.
5-day free pass. No card required.